Kelly McQuarrie

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Kim N., Andrew Protheroe, Gaetano Facchini et al. · The Lancet Oncology · 2018 · 163 citations

Patient-reported Outcomes, Urology, Genitourinary Cancer +8

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Fred Saad, David Cella, Ethan Basch et al. · The Lancet Oncology · 2018 · 128 citations

Quality Of Life, Urology, Health-related Quality +9

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell et al. · The Lancet Oncology · 2019 · 110 citations · Full text

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors

Heather L. Gelhorn, Sandra Tong, Kelly McQuarrie et al. · Clinical Therapeutics · 2016 · 105 citations · Full text

Effects of meal size and composition on incretin, α-cell, and β-cell responses

J.M. Rijkelijkhuizen, Kelly McQuarrie, Cynthia J. Girman et al. · Metabolism · 2009 · 63 citations

Nutrition, β-Cell Responses, Cellular Nutrition +9